These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
58 related articles for article (PubMed ID: 19176055)
1. [Effect of cytochrome CYP2C19 on the anti-myeloma activity of thalidomide in vitro]. Li YH; Hou J; Jiang H; Huang HM; Zhu R Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):654-7. PubMed ID: 19176055 [TBL] [Abstract][Full Text] [Related]
2. Metabolism of thalidomide by human liver microsome cytochrome CYP2C19 is required for its antimyeloma and antiangiogenic activities in vitro. Li Y; Jiang Z; Xiao Y; Li L; Gao Y Hematol Oncol; 2012 Mar; 30(1):13-21. PubMed ID: 21638302 [TBL] [Abstract][Full Text] [Related]
3. [Antiangiogenic activity of thalidomide in vitro mediated by cytochrome CYP2C19]. Li YH; Hou J; Jiang H; Huang HM Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):102-6. PubMed ID: 19236757 [TBL] [Abstract][Full Text] [Related]
4. [Effect of nuclear receptor inhibitor importazole on the proliferation and apoptosis of multiple myeloma cells]. Yan WQ; Du J; Jiang H; Hou J Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):323-6. PubMed ID: 23668205 [TBL] [Abstract][Full Text] [Related]
5. [Effect of 2-methoxyestradiol on proliferation and apoptosis of myeloma cell lines]. Gao WR; Hou J Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Apr; 13(2):293-7. PubMed ID: 15854295 [TBL] [Abstract][Full Text] [Related]
6. [Effects of As2O3, dexamethasone and thalidomide on apoptosis and cytoplasmic [Ca2+] of myeloma cell line U266]. Lin RF; Lu H; Liu P; Wang YR; Shen WY; Wu YJ; Zhang JF; Fei XM; Ge Z; Li JY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1200-3. PubMed ID: 18088466 [TBL] [Abstract][Full Text] [Related]
7. [Study on proliferation inhibiting and apoptosis inducing effects of cerulenin on multiple myeloma cells]. Wang WQ; Zhao XY; Xu GB; Liang Y Zhonghua Xue Ye Xue Za Zhi; 2006 Oct; 27(10):675-7. PubMed ID: 17343199 [TBL] [Abstract][Full Text] [Related]
8. [Effect of AZD8330 on proliferation and apoptosis of multiple myeloma cells]. Yao Y; Bian YP; Xia DD; Pan B; Niu MS; Zhao K; Zeng LY; Xu KL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1311-5. PubMed ID: 25338579 [TBL] [Abstract][Full Text] [Related]
9. Novel tubulin-polymerization inhibitor derived from thalidomide directly induces apoptosis in human multiple myeloma cells: possible anti-myeloma mechanism of thalidomide. Iguchi T; Yachide-Noguchi T; Hashimoto Y; Nakazato S; Sagawa M; Ikeda Y; Kizaki M Int J Mol Med; 2008 Feb; 21(2):163-8. PubMed ID: 18204782 [TBL] [Abstract][Full Text] [Related]
10. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Lasker JM; Wester MR; Aramsombatdee E; Raucy JL Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596 [TBL] [Abstract][Full Text] [Related]
11. [Effect of CYP2C19 gene polymorphism on efficacy of thalidomide-based regimens for the treatment of multiple myeloma]. Li YH; Hou J Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):651-4. PubMed ID: 18399167 [TBL] [Abstract][Full Text] [Related]
12. [Study on the relationship of beta-catenin level and sensitivity to Bortezomib of myeloma cell lines]. Zhou LL; Fu WJ; Yuan ZG; Wang DX; Hou J Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):234-7. PubMed ID: 18843976 [TBL] [Abstract][Full Text] [Related]
13. [Proliferation inhibiting and apoptosis inducing effects of parthenolide on human multiple myeloma cells]. Chen ZC; Li QB; Shao J; Lü J; You Y; Zhong ZD; Zou P Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1993-6. PubMed ID: 17064599 [TBL] [Abstract][Full Text] [Related]
14. [Effects of beta-elemene on proliferation and apoptosis of human multiple myeloma cell RPMI-8226]. Chen H; Shi L; Cheng ZY; Yao L; Yang YY; Pan L Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):368-71. PubMed ID: 20416170 [TBL] [Abstract][Full Text] [Related]
15. Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells. Yata K; Otsuki T; Kurebayashi J; Uno M; Fujii T; Yawata Y; Takata A; Hyodoh F; Sugihara T Int J Oncol; 2003 Jan; 22(1):165-73. PubMed ID: 12469200 [TBL] [Abstract][Full Text] [Related]
16. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Hirani VN; Raucy JL; Lasker JM Drug Metab Dispos; 2004 Dec; 32(12):1462-7. PubMed ID: 15448116 [TBL] [Abstract][Full Text] [Related]
17. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Wester MR; Lasker JM; Johnson EF; Raucy JL Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382 [TBL] [Abstract][Full Text] [Related]
18. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Karam WG; Goldstein JA; Lasker JM; Ghanayem BI Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508 [TBL] [Abstract][Full Text] [Related]
19. Resveratrol as a novel agent for treatment of multiple myeloma with matrix metalloproteinase inhibitory activity. Sun CY; Hu Y; Guo T; Wang HF; Zhang XP; He WJ; Tan H Acta Pharmacol Sin; 2006 Nov; 27(11):1447-52. PubMed ID: 17049120 [TBL] [Abstract][Full Text] [Related]
20. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Giraud C; Tran A; Rey E; Vincent J; Tréluyer JM; Pons G Drug Metab Dispos; 2004 Nov; 32(11):1279-86. PubMed ID: 15483195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]